RSV clinical trials

Explore recruiting rsv clinical trials.

Recruiting rsv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

RSV trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

Germany, Spain, Hungary, Finland, France, Norway +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.

Finland, Poland, Spain

Phase III and phase IV (Integrated) EU CTIS Study details

Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)

Germany, Spain, Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Global, Randomized, Modified Double-Blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine in Adults 60 Years of Age and Older.

Spain, Estonia, Bulgaria, Germany, Finland, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications

Slovakia, Spain, Poland, Czechia, Netherlands, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

RSV trials by city

RSV in Toronto RSV in Vancouver RSV in Montreal RSV in Calgary RSV in Edmonton RSV in Ottawa RSV in Winnipeg RSV in Quebec City RSV in Hamilton RSV in Kitchener RSV in London RSV in Halifax RSV in New York RSV in Los Angeles RSV in Chicago RSV in Houston

Other conditions

Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis B Hepatitis C COVID-19 Influenza Sickle cell disease Anemia Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus Hearing loss Chronic fatigue syndrome Obesity Type 2 diabetes